16 September 2026 editorial review · Trial
JAKPOT T1D: Abrocitinib and ritlecitinib in new-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT05743244; ACTIVE_NOT_RECRUITING; updated 2026-09-02; enrollment 78 (ESTIMATED); results not posted.
Endpoint comparison: The area under the stimulated C-peptide curve (Y_AUC) (12 Months).
Sources for this record: JAK inhibitors to preserve C-peptide production in new-onset T1D (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.